Jump to Main Content

Annual Meeting Press

Annual Meeting Press Program

ASH will host the following 60-minute live press briefings for credentialed media on site in Atlanta, Georgia, and via livestream on the annual meeting virtual platform. The briefings will include thematic overviews, brief presentations by each of the press presenters, and live Q&A. Embargoes for studies included in press briefings will lift at the start of the briefing (unless otherwise noted).

Diversification of Approaches to Care in Acute Leukemia Across Age and Race

Moderator: Mikkael Sekeres, MD
Briefing time: Saturday, December 11, 2021: 7 a.m. – 8 a.m. Eastern time

  • 109: Code Status Transitions in Patients with High-Risk Acute Myeloid Leukemia (AML) – presenter Hannah R. Abrams, MD
  • 697: AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation – presenter Stephan de Botton, MD
  • 211: Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children’s Oncology Group (COG) Study – presenter Sumit Gupta, MD
  • 337: Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data – presenter Lori Muffly, MD, MS

Immune System 1, Cancer 0: Advances in Immunotherapy

Moderator: Laurie Sehn, MD
Briefing time: Saturday, December 11, 2021: 8:30 a.m. – 9:30 a.m. Eastern time

  • 463: Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial – presenter Hartmut Goldschmidt, MD
  • 127: Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study – presenter L. Elizabeth Budde
  • 91: Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study – presenter Manali Kamdar, MD
  • 2: Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma – presenter Frederick L. Locke, MD

Potential Prevention or Protection? New Insights into Blood Disorders

Moderator: Joseph Mikhael, MD
Briefing time: Saturday, December 11, 2021: 10:30 a.m. – 11:30 a.m. Eastern time

  • 152: High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study – presenter Irene Ghobrial, MD
  • 5: Clonal Hematopoiesis Is Associated with Protection from Alzheimer’s Disease – presenter Sidd Jaiswal, MD
  • 573: Restoring Iron Homeostasis in Pts Who Achieved Transfusion Independence after Treatment with Betibeglogene Autotemcel Gene Therapy: Results from up to 7 Years of Follow-up – presenter Alexis A. Thompson, MD, MPH

COVID-19, 20, 21: Profiling the Latest Risks for Patients with Blood Disorders in a Time of COVID

Moderator: Laura Michaelis, MD
Briefing time: Saturday, December 11, 2021: 12:30 p.m. – 1:30 p.m. Eastern time

  • 3040: Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology – presenter Lisa K. Hicks, MD, MSc
  • 280: Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub – presenter Pinkal Desai, MD, MPH
  • 3105: COVID-19 Infection and Outcomes at a Comprehensive Sickle Cell Center – presenter Fuad El Rassi, MD
  • 218: Antibody Response to Vaccination with BNT162b2, mRNA-1273, and ChADOx1 in Patients with Myeloid and Lymphoid Neoplasms – presenter Susanne Saussele, MD
  • 217: Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia – presenter Jeffrey Lancet, MD

Selected Late-Breaking Abstracts

Note that the embargo on late-breaking abstracts will NOT lift at the start of this press briefing. The embargo will lift at the start of the full late-breaking abstracts session on Tuesday, December 14, at 9 a.m. Eastern time.

Moderator: Jane N. Winter, MD
Briefing time: Monday, December 13, 2021: 7:30 a.m. – 8:30 a.m. Eastern time

  • LBA-1: The Polarix Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma – presenter Gilles Salles, MD
  • LBA-3: Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B) – presenter Alok Srivastava, MD
  • LBA-6: Tisagenlecleucel Vs Standard of Care as Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study – presenter Michael R. Bishop, MD